Raglan has a long successful history of providing corporate finance and investment banking services to a range of Irish and international companies. For the last number of years, Raglan ceased providing any third-party corporate finance services and is now solely focused upon creating our own companies in-house that can then be rapidly listed on the London stock exchange. Our general target is to complete an IPO within two years post inception of the company.

Raglan established a niche pharma services company, Open Orphan in 2017, following on from the success of its first rare disease pharma company, Amryt Pharma plc. Open Orphan is a rapidly growing niche CRO pharmaceutical services company, which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan is led by an experienced Board and management team with deep industry and financial expertise.

Open Orphan is now a world leader in the testing of vaccines and antiviral through the use of challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan completed its IPO in June 2019 via the reverse takeover of Venn Life Sciences and in January 2020 completed a merger with hVIVO. It is now listed on the London AIM stock exchange and the Euronext growth exchange.

Open Orphan plc’s subsidiary hVIVO is now offering COVID Clear Test, the most accurate antibody test available to UK and Irish employers, helping them to get their people back to work. Having recently secured the rights from Quotient for their antibody testing platform which detects with 100% accuracy antibodies when present (unlike finger prick tests which MHRA advised against), hVIVO is now formally offering antibody testing to customers from Thursday 4 June 2020. This is the first time that such on demand testing is made available to employer groups in the UK and Ireland, hVIVO’s equipment has the capability to run 3,000 samples per day, 21,000 per week, 1 million per year. Samples will be tested in the London laboratory with results returned within 48 hours.

In 2016, Raglan established Amryt Pharma Plc which is also listed on the London AIM, Dublin Euronext and the NASDAQ exchanges. Following Amryt’s acquisition of Aegerion Pharmaceuticals in September 2019, it had a market capitalisation in excess of £281m in June 2020 and is now an established European and North America orphan drug company. The company already has rapidly growing monthly sales revenues while at the same time managing a pipeline of drugs in development including its potential blockbuster EB orphan drug, which is now in its final FDA phase three trials.

Raglan has also been very active in the Oil & Gas sector for many years, therefore having an in-depth knowledge of the industry having completed a variety of related projects. Raglan established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m.

The team behind Raglan Capital have many years of deal making experience with a proven track record of achieving exceptional results.

Raglan has offices in Dublin, London and Vienna. Our relationships include regular contact with the Dublin and international stockbrokers, investment banks, private equity firms and a broad range of investors which provides Raglan Capital with invaluable access to local advisers and contacts when completing international transactions.